Skip to main content
. 2004 Nov;165(5):1743–1753. doi: 10.1016/S0002-9440(10)63429-3

Figure 8.

Figure 8

Inhibition of HB-EGF processing by ADAM inhibitor in glioblastoma tissues and U251 glioblastoma cells. A: Glioblastoma tissues were cultured in the presence (lanes 2 and 4) and absence (lanes 1 and 3) of KB-R7785, and HB-EGF species were analyzed by immunoblotting as described in Materials and Methods. ProHB-EGF and active HB-EGF species are indicated by arrowheads and arrows, respectively. The membrane was reprobed with anti-β-actin antibody. Two representative cases are shown. B: U251 glioblastoma cells were cultured in the presence (lanes 2 and 4) and absence (lanes 1 and 3) of KB-R7785, and biotinylated proHB-EGF species (arrowheads) were immunoprecipitated with anti-HB-EGF antibody (lanes 1 and 2) or nonimmune IgG (lanes 3 and 4) as described in Materials and Methods. As for a control, β-actin was immunoblotted as described in Materials and Methods.